Metastatic Esophageal Squamous Cell Carcinoma Successfully Treated with Immunotherapy: First Case Report in Thailand.

Main Article Content

Potjana Jitawatanarat, MD
Prasert Lertsanguansinchai, MD
Surachat Chakrapee-sirisuk, MD


Metastatic esophageal carcinoma is considered one of the worst prognosis cancersworldwide. The goals of treatment are usually symptoms palliation and possible lifeprolongation. In recent years, the field of immuno-oncology has shown promising treatmentresults and caused a paradigm shift in many types of cancer, as the response is quitelong-lasting. Anti-programmed cell death 1 (anti PD-1) is one of the immuno-oncologydrugs which has been investigated in many types of cancer and currently has beenapproved to be used in melanoma, lung cancer, kidney cancer and bladder cancer. Wereport a case of metastatic esophageal squamous cell carcinoma which had been heavilypretreated but presented an almost complete response to the anti PD-1, pembrolizumab.


Download data is not yet available.

Article Details

How to Cite
Jitawatanarat P, Lertsanguansinchai P, Chakrapee-sirisuk S. Metastatic Esophageal Squamous Cell Carcinoma Successfully Treated with Immunotherapy: First Case Report in Thailand. BKK Med J [Internet]. 2016Sep.20 [cited 2020Jul.15];12(1):87. Available from:
Case Report


1. International Agency for Research on Cancer (IARC). GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. (Accessed July 9, 2016 at lation.aspx).
2. National Cancer Institute (NIH): Surveillance, Epidemi ology, and End Results Program (SEER). SEER Cancer statistics review (CSR) 1975-2013. (Accessed July 9, 2016 at php sectionSEL=8&pageSEL=sect_08_table.08.html).
3. Lagergren J, Bergstrom R, Lindgren A, et al. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer 2000; 85:340-6.
4. Engel LS, Chow WH, Vaughan TL, et al. Population at tributable risks of esophageal and gastric cancer. J Natl Cancer Inst 2003;95:1404-13.
5. Freedman ND, Abnet CC, Leitzmann MF, et al. A pro- spective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol 2007;165:1424-33.
6. Vaughan TL, Davis S, Kristal A, et al. Obesity, alcohol, and tobacco as risk factors for cancers of esophagus and gastric cardia: adenocarcinoma versus squamous cell car- cinoma. Cancer Epidemiol Biomarkers Prev 1995;4:85- 92.
7. Powell NB, Schechtman KB, Riley RW, et al. Sleepy driving: accidents and injury. Otolaryngol Head Neck Surg 2002;126:217-27.
8. Korman AJ, Peggs KS, Allison JP. Checkpoint blockage in cancer immunotherapy. Adv Immunol 2006;90:297- 339.
9. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
10. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
11. Hodi FS, O’Day SJ, McDermott DF, et al. Improved sur- vival with ipilimumab in patients with metastatic mela- noma. N Engl J Med 2010;363:711-23.
12. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372:2018-28.
13. Le DT, Uram JN, Wang H, et al. PD-1 blockage in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372:2509-20.
14. Doi T, Piha-Paul SA, Jalal SI, et al. Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab (MK-3475). J Clin Oncol 34, 2016 (suppl 4S; abstr 7).
15. A service of the U.S. National Insti- tutes of Health. Study of Pembrolizumab (MK-3475) versus investigator‘s choice standard therapy for partici- pants with advanced esophageal/esophagogastric junction carcinoma that progressed after first-line therapy (MK- 3475-181/KEYNOTE-181) 2016. (Accessed July 9, 2016 at